Novo Nordisk A/S ( NVO) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.6%. By the end of trading, Novo Nordisk A/S rose 77 cents (0.6%) to $141.48 on average volume. Throughout the day, 272,128 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 294,600 shares. The stock ranged in a price between $140.38-$141.55 after having opened the day at $140.81 as compared to the previous trading day's close of $140.71. Other companies within the Drugs industry that increased today were: Rosetta Genomics ( ROSG), up 39.2%, Supernus Pharmaceuticals ( SUPN), up 8.6%, Skystar Bio-Pharmaceutical Company ( SKBI), up 6.8%, and ProPhase Labs ( PRPH), up 6.8%. Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $82.2 billion and is part of the health care sector. The company has a P/E ratio of four, below the average drugs industry P/E ratio of 25.5 and below the S&P 500 P/E ratio of 17.7. Shares are up 22.1% year to date as of the close of trading on Thursday. Currently there are two analysts that rate Novo Nordisk A/S a buy, no analysts rate it a sell, and two rate it a hold. TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.